Therefore, it can be hypothesized that a therapeutic advantage is achieved in BRAF mutant melanoma tumors by first blocking OXPHOS and adaptation to hypoxia with BAY 87-2243, followed by subsequent downregulating of glycolysis using vemurafenib. Here, BRAF is linked to melanoma.